Abstract
The aim of this study is to evaluate if mitomycin C (MMC), applied topically at the site of maxillary antrostomy in experimentally inflamed maxillary sinuses, may reduce postoperative ostial stenosis without any harmful effect. Twenty-four rabbits with experimentally induced maxillary sinusitis underwent maxillary antrostomy bilaterally. MMC at a concentration of 0.4 or 1 mg/ml was applied at the site of antrostomy on the right whilst the antrostomy site on the left served as the control. Half of each MMC concentration group of animals were killed after 3 weeks, and the remaining half after 6 weeks. For every rabbit, the areas of antrostomies were measured and mucosal specimens around the ostia were obtained for microscopic evaluation at the time of antrostomy and killing. Within each MMC concentration group, MMC-treated antrostomies were significantly wider than those of the controls (P < 0.05), even after 6 weeks. However, comparison of the areas of MMC-treated antrostomies between the two MMC concentration groups did not show any significant difference (P > 0.05). No systemic side effect or permanent mucosal damage was detected. These results suggest that postoperative topical MMC at a concentration of 0.4 mg/ml can be used to prolong the patency of maxillary antrostomy in an inflammed sinus.
MeSH Terms
Administration, Topical
Animals
Antibiotics, Antineoplastic/administration & dosage,pharmacology
Cicatrix/prevention & control
Disease Models, Animal
Male
Mitomycin/administration & dosage,pharmacology
Postoperative Complications/prevention & control
Rabbits
Sinusitis/drug therapy,surgery
Statistics, Nonparametric
Wound Healing/drug effects
Chemicals
Antibiotics, Antineoplastic
Mitomycin
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Park Seok-Won
Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Dongguk University, Goyang, South Korea.
Koo Bon Seok
Park Yong Ho
Jin Yong De
Rha Ki Sang
References (13)
13 references, click to expand
-
Use of mitomycin C for maintaining myringotomy patency.
Otolaryngol Head Neck Surg. 2000 Jan;122(1):8-10
PMID: 10629475
-
Mitomycin as adjunct chemotherapy with trabeculectomy.
Ophthalmology. 1991 Mar;98(3):317-21
PMID: 2023752
-
Low-dose and high-dose mitomycin trabeculectomy as an initial surgery in primary open-angle glaucoma.
Ophthalmology. 1993 Nov;100(11):1624-8
PMID: 8233386
-
Long-term outcome analysis of functional endoscopic sinus surgery: correlation of symptoms with endoscopic examination findings and potential prognostic variables.
Laryngoscope. 1997 Apr;107(4):504-10
PMID: 9111381
-
Sinus surgery: does mitomycin C reduce stenosis?
Laryngoscope. 1998 Jun;108(6):883-6
PMID: 9628504
-
Effect of brief exposure to mitomycin C on cultured human nasal mucosa fibroblasts.
Ophthal Plast Reconstr Surg. 2000 Mar;16(2):119-25
PMID: 10749158
-
Antifibrosis agents and glaucoma surgery.
Invest Ophthalmol Vis Sci. 1994 Oct;35(11):3789-91
PMID: 7928175
-
Mitomycin C in sinus surgery: preliminary results in a rabbit model.
J Otolaryngol. 2001 Feb;30(1):1-5
PMID: 11770965
-
Mitomycin: effects on laryngeal and tracheal stenosis, benefits, and complications.
Ann Otol Rhinol Laryngol. 2001 Jan;110(1):1-6
PMID: 11201800
-
Surgical causes of failure in endoscopic sinus surgery.
Laryngoscope. 1999 Jan;109(1):27-9
PMID: 9917035
-
Preventing myringotomy closure with topical mitomycin C in rats.
Otolaryngol Head Neck Surg. 1999 Jun;120(6):794-8
PMID: 10352429
-
Can topical mitomycin prevent laryngotracheal stenosis?
Laryngoscope. 1999 Oct;109(10):1594-600
PMID: 10522927
-
Activation and suppression of fibroblast function.
Eye (Lond). 1994;8 ( Pt 2):188-95
PMID: 7958020